Corcept Therapeutics Incorporated Stock 12‑Month Price Target Raised to $142.6, Implies 74% Upside
Analysts raised Corcept Therapeutics' (CORT) average price target to $142.6, up from $141, with a range of $50 to $173. This implies 74% upside from the Nov. 3 close. The consensus rating is 'Buy' from 7 analysts, with 5 Buys, 1 Hold, and 1 Sell.
How this was made

The 30-second read
Why it matters
Analyst consensus remains a Buy, with a slight upward revision in price targets, indicating modest optimism.
Market read
The price‑target lift provides a mild bullish cue but lacks a decisive catalyst for immediate trading.
What to watch
Potential risks from clinical trial outcomes or regulatory decisions could offset the target raise.
Background
Corcept Therapeutics is a specialty pharmaceutical company focused on cortisol‑related therapies.
Market effects
Minimal; the change reflects analyst sentiment on Corcept rather than a sector‑wide shift.
Limited to US biotech/pharma investors.
Low; no broader macro or global impact.
Counterpoint
Some investors may view the modest target increase as already priced in, limiting upside.
Key entities
- companyCorcept Therapeutics Incorporated
US‑listed biotech firm (NASDAQ: CRCT).

